BULLISHWHALES
BullishWhales · Analysts · Analyst Profile
BW Score Rank#32 of 347

Silvan Tuerkcan

JMP Securities · Equity Research Analyst
ProvisionalActive since 2022
63BW ScoreSolid

Analyst rating accuracy & track record

Silvan Tuerkcan is an equity research analyst at JMP Securities. Bullish Whales has scored 40 of their stock calls across 11 companies. Their picks beat their sector 49% of the time over the next 12 months, and their price targets were reached 29% of the time within a year.

Win % vs sector
49%
PT Hit % (12mo)
29%
Avg sector-excess
+4.5%
Scored calls
40
Tickers
11
Tier
Provisional

Track record

Bullish Whales has scored 40 of Silvan Tuerkcan's stock calls across 11 companies, dating back to 2022. Their rated stocks beat their own sector 49% of the time over the next 12 months. On a typical call, a Tuerkcan pick returned +4.5% more than its sector over the following year.

Of the scored calls, 40 were bullish (Buy). Most of their coverage sits in Healthcare. Every number on this page is an estimate from our own data. It is for education only and is not investment advice.

Coverage & ratings

Rating mix (scored calls)
Sector coverage

Ratings & price targets

StockRatingPrice targetRated12-mo vs sectorPT hit
CNTXContext Therapeutics Inc
Buy$4.00Jun 2025+243.7%Miss
NUVBNuvation Bio Inc
Buy$6.00Jun 2025+88.0%Hit
TSHATaysha Gene Therapies Inc
Buy$6.00May 2025+101.9%Hit
FHTXFoghorn Therapeutics Inc
Buy$9.00May 2025−25.4%Miss
BNTCBenitec Biopharma Ltd ADR
Buy$20.00May 2025−26.5%Miss
FHTXFoghorn Therapeutics Inc
Buy$9.00Apr 2025+5.4%Miss
ENGNenGene Holdings Inc. Common Stock
Buy$18.00Apr 2025+66.5%Miss
TSHATaysha Gene Therapies Inc
Buy$5.00Apr 2025+241.0%Hit
FHTXFoghorn Therapeutics Inc
Buy$9.00Apr 2025+7.8%Miss
NUVBNuvation Bio Inc
Buy$6.00Apr 2025+128.3%Hit
BNTCBenitec Biopharma Ltd ADR
Buy$20.00Apr 2025−19.1%Miss
ACRVAcrivon Therapeutics, Inc. Common Stock
Buy$17.00Mar 2025−46.0%Miss
BNTCBenitec Biopharma Ltd ADR
Buy$18.00Mar 2025−27.3%Miss
CNTXContext Therapeutics Inc
Buy$4.00Jan 2025+32.9%Miss
ENGNenGene Holdings Inc. Common Stock
Buy$18.00Dec 2024+32.7%Miss
RLAYRelay Therapeutics Inc
Buy$21.00Dec 2024+59.3%Miss
VORVor Biopharma Inc
Buy$12.00Dec 2024−56.2%Miss
ENGNenGene Holdings Inc. Common Stock
Buy$18.00Dec 2024−3.2%Miss
ENGNenGene Holdings Inc. Common Stock
Buy$18.00Nov 2024−18.5%Miss
BNTCBenitec Biopharma Ltd ADR
Buy$18.00Oct 2024+58.7%Miss
BNTCBenitec Biopharma Ltd ADR
Buy$16.00Sep 2024+35.4%Hit
ACRVAcrivon Therapeutics, Inc. Common Stock
Buy$17.00Sep 2024−69.1%Miss
VORVor Biopharma Inc
Buy$12.00Sep 2024+91.2%Miss
MGNXMacroGenics Inc
Buy$8.00Jul 2024−48.8%Miss
CLLSCellectis SA
Buy$6.00May 2024−37.0%Miss
VORVor Biopharma Inc
Buy$12.00May 2024−83.5%Miss
MGNXMacroGenics Inc
Buy$16.00May 2024−60.0%Miss
ACRVAcrivon Therapeutics, Inc. Common Stock
Buy$17.00Apr 2024−80.8%Miss
BNTCBenitec Biopharma Ltd ADR
Buy$16.00Apr 2024+103.8%Hit
ACRVAcrivon Therapeutics, Inc. Common Stock
Buy$14.00Apr 2024−75.9%Miss
BNTCBenitec Biopharma Ltd ADR
Buy$10.00Feb 2024+276.6%Hit
BNTCBenitec Biopharma Ltd ADR
Buy$8.00Jan 2024+258.9%Hit
CLLSCellectis SA
Buy$6.00Nov 2023−58.5%Miss
BNTCBenitec Biopharma Ltd ADR
Buy$6.00Sep 2023+175.2%Hit
CLLSCellectis SA
Buy$6.00Aug 2023+0.8%Miss
BNTCBenitec Biopharma Ltd ADR
Buy$4.00Jun 2023+42.6%Miss
BNTCBenitec Biopharma Ltd ADR
Buy$4.00May 2023+157.7%Miss
CLLSCellectis SA
Buy$6.00Mar 2023+14.1%Miss
CLLSCellectis SA
Buy$6.00Jan 2023−18.0%Miss
BNTCBenitec Biopharma Ltd ADR
Buy$4.00Oct 2022−8.0%Miss
Go to

Silvan Tuerkcan: analyst track record FAQ

Is Silvan Tuerkcan a good stock analyst?

Yes, by track record. Silvan Tuerkcan ranks number 32 of 347 of the analysts Bullish Whales scores, with a BW Score of 63 out of 100. Past results do not guarantee future ones.

What is Silvan Tuerkcan's win rate?

Silvan Tuerkcan's win rate is 49%. Across 40 scored calls, their rated stocks beat their sector 49% of the time over the next 12 months. On a typical call they returned +4.5% more than the sector.

What stocks and sectors does Silvan Tuerkcan cover?

Silvan Tuerkcan covers 11 companies, with the most coverage in Healthcare. See the ratings table above for every scored call and its outcome.

Are Silvan Tuerkcan's price targets accurate?

Silvan Tuerkcan's price targets are reached within 12 months 29% of the time. The base rate across all analysts Bullish Whales tracks is about 43 percent.

How accurate are Wall Street analyst price targets?

Most analyst price targets are not reached on schedule. Across every target Bullish Whales scores, the stock reaches the target within 12 months only about 43 percent of the time, which is why it helps to compare hit rates analyst by analyst.

Should I follow Silvan Tuerkcan's stock ratings?

Their track record is strong, but no analyst is right every time. Follow the long-term track record rather than any single rating, size your positions to your own risk, and treat this as research, not investment advice.

How does Bullish Whales score analyst accuracy?

Bullish Whales scores every rating on real prices. We enter at the closing price on or after the call date, with no look-ahead, then measure the 12-month return above the stock's sector ETF and check whether the price target was reached. Scores are pulled toward the population average and corrected for testing thousands of analysts at once, so they reflect repeatable skill rather than luck.

How does Silvan Tuerkcan rank among Wall Street analysts?

Silvan Tuerkcan ranks number 32 of 347 by BW Score. We rank analysts by their realized 12-month sector-excess return and require a minimum number of calls so a few lucky picks cannot reach the top.

FREE BULLISHWHALES ACCOUNT
Silvan Tuerkcan's picks beat their sector 49% of the time. Catch the next one.
Get a free alert the second they issue a new rating, and unlock every analyst's win rate and price-target accuracy.
Get free analyst alerts →
ST
63
SOLID
Ranked #32
of 347 analysts

Browse the full analyst leaderboardHow analyst accuracy is scored

Every score, Win %, PT Hit % and rank is an estimate Bullish Whales calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.

v1.0.30